After leaving troubled Arrowhead and RNA, Steven Kanner turns to CRISPR – FierceBiotech
FierceBiotech |
After leaving troubled Arrowhead and RNA, Steven Kanner turns to CRISPR
FierceBiotech Caribou Biosciences has seen biopharma vet and former VP of discovery biology at Arrowhead Steven Kanner join the biotech as the CRISPR R&D race continues apace. Kanner comes on board as CSO and will now lead Caribou’s research into new … |
The Sun |
Combo immunotherapy may herald new standard of care for kidney cancer
Science Daily Targeted therapies have prolonged life expectancy, but are associated with daily side effects. Single-agent immunotherapies improve patients’ survival, but only benefit a subset of patients. Combination immunotherapy with nivolumab and ipilimumab as … Measuring T Cell Levels May Help Identify Patient Response to ImmunotherapySpecialty Pharmacy Times What is immunotherapy, could Bradley Lowery be helped by the cancer treatment cost and how much does it cost?The Sun Combo immunotherapy may change treatment for kidney cancerUPI.com Immuno-Oncology News –PR Newswire (press release) all 6 news articles » |
The Sun |
Combo immunotherapy may herald new standard of care for kidney cancer
Science Daily Targeted therapies have prolonged life expectancy, but are associated with daily side effects. Single-agent immunotherapies improve patients’ survival, but only benefit a subset of patients. Combination immunotherapy with nivolumab and ipilimumab as … Measuring T Cell Levels May Help Identify Patient Response to ImmunotherapySpecialty Pharmacy Times What is immunotherapy, could Bradley Lowery be helped by the cancer treatment cost and how much does it cost?The Sun Combo immunotherapy may change treatment for kidney cancerUPI.com PR Newswire (press release) all 6 news articles » |
Investor’s Business Daily |
Novartis Is Going Before The FDA — But Kite Could Benefit More
Investor’s Business Daily CAR–T therapies involve removing immune cells from a patient’s blood and then programming them to seek out and destroy cancer cells. But some of these therapies have proven toxic to the nervous system. Meanwhile, the lag in turnaround time remains a … |